January 26, 2022

DistilMotionDexter400x275Switzerland-based Distalmotion has announced raising $90 million in Series E financing to help support the global commercialization of its surgical robot, Dexter. Revival Healthcare Capital led the funding round, with participation from 415 Capital and existing investors.

The CE-marked Dexter aims to shift the paradigm of robotic surgery by bringing the surgeon back into the sterile field, allowing direct patient access at all times and integrating proven laparoscopic workflows into the robotic setup, the company said. The user-centric approach makes the surgeon the focal point of the procedure, reducing complexity and delivering simplicity and versatility to the robotic surgery market.

“Dexter combines the best of both worlds – laparoscopy and robotics – to make sense of robotic surgery,” said Michael Friedrich, CEO of Distalmotion. “By addressing essential problems that operating room teams face, we can deliver on our mission to fast-track widespread adoption of robotic surgery in minimally invasive care. We are thrilled to have found the best-fitting partners to execute and deliver on this global purpose.”

The new funding follows the completion of Dexter’s first clinical cases, and will support the company’s commercial scaling. Distalmotion said leading European hospitals are developing procedure guidelines and training protocols for robotic surgery with Dexter as part of clinical studies and an early adopter program. In addition, Distalmotion said it will work closely with the U.S. Food and Drug Administration (FDA) on a U.S. submission, supported by the financing.

“This is a fundamentally new approach to robotic surgery,” said Dieter Hahnloser, who heads colorectal surgery at Lausanne University Hospital and performed the world’s first general surgery procedure with Dexter in 2021. “Dexter’s open platform and the ability to switch quickly between standard laparoscopy and the robot give me an added sense of control and the freedom of choice to use the best instruments available for the job. To have these benefits while remaining sterile, with direct access to patient and robot, indicates Dexter can be a gamechanger in ORs around the world.”

For more details on the Dexter robot’s technology, visit the Distalmotion website here.

Related video: